Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mifepristone in Breast Cancer with High PRA/PRB Ratio (MIPRA)
NCT02651844Completed
- Sponsor
- Hospital Magdalena V. de Martínez
- Start
- Apr 2016
- Primary completion
- Oct 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of mifepristone in breast cancer, sponsored by Hospital Magdalena V. de Martínez. Primary endpoint: Decrease in tumor cell proliferation (Ki-67) at 14 days. Started Apr 2016; status: completed.
02
Drugs
mifepristone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02651844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02651844.